Core Viewpoint - The company plans to temporarily use part of its idle raised funds, not exceeding RMB 30 million, to supplement its working capital while ensuring that the investment projects are not affected [2][4][5] Summary by Sections 1. Basic Situation of Raised Funds - The company issued 33,333,334 shares at a price of RMB 16.43 per share, raising a total of RMB 547,666,677.62 [1] - The total issuance costs amounted to RMB 49,653,236.30, including various fees [1] 2. Situation of Investment Projects - The company has a total of RMB 500,816,900.00 planned for investment in projects related to bone regeneration and artificial bone repair materials [2] - As of June 30, 2025, the unused balance of raised funds was RMB 819,299,209.1 (including interest) [2] 3. Plan for Using Idle Funds - The company intends to use up to RMB 30 million of idle raised funds for working capital, with a usage period not exceeding 12 months [2][3] - The funds will only be used for business expansion and daily operations related to the main business [3] 4. Review Procedures and Special Opinions - The board of directors and the supervisory board approved the use of idle funds, which does not require shareholder meeting approval [4] - The supervisory board believes this action will meet the company's working capital needs and improve the efficiency of idle fund usage [4] 5. Sponsor's Verification Opinion - The sponsor confirmed that the company followed necessary approval procedures and that the use of idle funds will not affect the investment projects [4][5]